Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ARS Pharmaceuticals, Inc.SPRY · Entity 883 | Director | June 24, 2026 | June 26, 2026 |
| Nkarta, Inc.NKTX · Entity 6346 | Director | June 08, 2022 | June 10, 2022 |
| Relay Therapeutics, Inc.RLAY · Entity 4044 | Director | June 03, 2024 | June 06, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ARS Pharmaceuticals, Inc.
Report date June 24, 2026 · Filed June 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.54 · Expires 2036-06-23 | Direct | 30,000 |
Reported balance
After 2026-06-24 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-24 · Grant · Acquired 30,000 · Balance 30,000 F1: The shares subject to the option will vest in full on the earlier of June 24, 2027 or the date of the Issuer's 2027 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option will vest in full on the earlier of June 24, 2027 or the date of the Issuer's 2027 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors.
Nkarta, Inc.
Report date June 08, 2022 · Filed June 10, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.95 · Expires 2032-06-07 | Direct | 16,000 |
Reported balance
After 2022-06-08 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-06-08 · Grant · Acquired 16,000 · Balance 16,000 F1: All shares subject to the option vest 100% on the first to occur of (i) June 8, 2023 or (ii) the day immediately preceding the first annual meeting of the Issuer's stockholders to occur after the date of grant of the award. Each grant, to the extent outstanding and otherwise unvested, will become fully vested should a "change in control" of the Issuer occur (as described in the applicable award agreement) or upon the Reporting Person's separation from service with the Issuer due to the Reporting Person's death or "disability" (as described in the applicable award agreement). |
Filing footnotes · ownership attribution and instrument terms
F1: All shares subject to the option vest 100% on the first to occur of (i) June 8, 2023 or (ii) the day immediately preceding the first annual meeting of the Issuer's stockholders to occur after the date of grant of the award. Each grant, to the extent outstanding and otherwise unvested, will become fully vested should a "change in control" of the Issuer occur (as described in the applicable award agreement) or upon the Reporting Person's separation from service with the Issuer due to the Reporting Person's death or "disability" (as described in the applicable award agreement).
Relay Therapeutics, Inc.
Report date June 03, 2024 · Filed June 06, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.79 · Expires 2034-06-02 | Direct | 102,225 |
Reported balance
After 2024-06-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-06-03 · Grant · Acquired 102,225 · Balance 102,225 F1: This option was granted on June 3, 2024 with respect to 102,225 shares of the Issuer's common stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was granted on June 3, 2024 with respect to 102,225 shares of the Issuer's common stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the grant date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Synthorx, Inc.
Report date January 23, 2020 · Filed January 24, 2020
Section 16 reporting ended · disclosed 2020-01-24. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 215,595 |
Reported balance
After 2020-01-08 transaction · row 1
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 1 · 2020-01-08 · Gift · Disposed 80,706 · Balance 215,595 |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-01-23 transaction · row 2
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 2 · 2020-01-23 · Other · Disposed 220,595 · Balance 0 F1: Includes 5,000 shares of Common Stock that were acquired by the Reporting Person on January 22, 2020 pursuant to the Issuer's Employee Stock Purchase Plan. |
| Common StockSEC Table I · non-derivative | IndirectBy Laura K. Shawver Trust DTD 3/20/2000 | 0 |
Reported balance
After 2020-01-23 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2020-01-23 · Other · Disposed 25,000 · Balance 0 |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.93 · Expires 2028-05-16 | Direct | 0 |
Reported balance
After 2020-01-23 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-01-23 · Disposition to issuer · Disposed 293,177 · Balance 0 F2: This option, which provided for vesting of 27,695 shares on April 12, 2019, with the remaining 363,944 shares vesting in equal monthly installments thereafter over the next 36 months, was cancelled in connection with the merger of the Issuer with Sanofi's wholly owned subsidiary in exchange for a cash payment of $19,663,381.39, representing the difference between the exercise price of the option and the market value of the underlying common stock of the Issuer on the effective date of the merger ($68). |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.63 · Expires 2027-12-06 | Direct | 0 |
Reported balance
After 2020-01-23 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2020-01-23 · Disposition to issuer · Disposed 172,264 · Balance 0 F3: This option, which provided for vesting of 25% of the shares one year after November 27, 2017, with the balance vesting in equal monthly installments thereafter over the next 36 months, was cancelled in connection with the merger of the Issuer with Sanofi's wholly owned subsidiary in exchange for a cash payment of $11,605,425.68, representing the difference between the exercise price of the option and the market value of the underlying common stock of the Issuer on the effective date of the merger ($68). |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.00 · Expires 2028-12-05 | Direct | 0 |
Reported balance
After 2020-01-23 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2020-01-23 · Disposition to issuer · Disposed 385,185 · Balance 0 F4: This option, which provided for vesting of 33.333% of the shares on December 18, 2019, with 66.667% of the shares subject to the option vesting upon certification by the Compensation Committee of the Board of Directors of the Issuer that the Issuer has received the first approval for commercial sale by a regulatory authority of any product candidate of the Issuer in any territory in the world, was cancelled in connection with the merger of the Issuer with Sanofi's wholly owned subsidiary in exchange for a cash payment of $21,955,545.00, representing the difference between the exercise price of the option and the market value of the underlying common stock of the Issuer on the effective date of the merger ($68). |
Filing footnotes · ownership attribution and instrument terms
F1: Includes 5,000 shares of Common Stock that were acquired by the Reporting Person on January 22, 2020 pursuant to the Issuer's Employee Stock Purchase Plan.
F2: This option, which provided for vesting of 27,695 shares on April 12, 2019, with the remaining 363,944 shares vesting in equal monthly installments thereafter over the next 36 months, was cancelled in connection with the merger of the Issuer with Sanofi's wholly owned subsidiary in exchange for a cash payment of $19,663,381.39, representing the difference between the exercise price of the option and the market value of the underlying common stock of the Issuer on the effective date of the merger ($68).
F3: This option, which provided for vesting of 25% of the shares one year after November 27, 2017, with the balance vesting in equal monthly installments thereafter over the next 36 months, was cancelled in connection with the merger of the Issuer with Sanofi's wholly owned subsidiary in exchange for a cash payment of $11,605,425.68, representing the difference between the exercise price of the option and the market value of the underlying common stock of the Issuer on the effective date of the merger ($68).
F4: This option, which provided for vesting of 33.333% of the shares on December 18, 2019, with 66.667% of the shares subject to the option vesting upon certification by the Compensation Committee of the Board of Directors of the Issuer that the Issuer has received the first approval for commercial sale by a regulatory authority of any product candidate of the Issuer in any territory in the world, was cancelled in connection with the merger of the Issuer with Sanofi's wholly owned subsidiary in exchange for a cash payment of $21,955,545.00, representing the difference between the exercise price of the option and the market value of the underlying common stock of the Issuer on the effective date of the merger ($68).
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 23, 2020 Filed Jan 24, 2020 23:41 UTC | Synthorx, Inc. THOR · Entity 152202 | OtherCommon Stock | 220,595 | $68.00 | $15,000,460.00 |
DisclosureSEC source: 0001209191-20-004929 · doc4.xml · nonDerivative · entry 2 Shawver Laura · CIK 0001551891 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: Includes 5,000 shares of Common Stock that were acquired by the Reporting Person on January 22, 2020 pursuant to the Issuer's Employee Stock Purchase Plan. Read SEC document |
| January 08, 2020 Filed Jan 24, 2020 23:41 UTC | Synthorx, Inc. THOR · Entity 152202 | GiftCommon Stock | 80,706 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-004929 · doc4.xml · nonDerivative · entry 1 Shawver Laura · CIK 0001551891 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 215,595 Read SEC document |
| December 30, 2019 Filed Jan 2, 2020 21:39 UTC | Synthorx, Inc. THOR · Entity 152202 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 120,815 | $0.00 Strike: $11.00 | $0.00 |
DisclosureSEC source: 0001209191-20-000319 · doc4.xml · derivative · entry 10 Shawver Laura · CIK 0001551891 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 385,185 Underlying: Common Stock · 120,815 shares Expires 2028-12-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 33.333% of the shares vested on December 18, 2019. 66.667% of the shares subject to the option vest upon certification by the Compensation Committee of the Board of Directors of the Issuer that the Issuer has received the first approval for commercial sale by a regulatory authority of any product candidate of the Issuer in any territory in the world. Read SEC document |
| December 30, 2019 Filed Jan 2, 2020 21:39 UTC | Synthorx, Inc. THOR · Entity 152202 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 147,264 | $0.00 Strike: $0.63 | $0.00 |
DisclosureSEC source: 0001209191-20-000319 · doc4.xml · derivative · entry 9 Shawver Laura · CIK 0001551891 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 172,264 Underlying: Common Stock · 147,264 shares Expires 2027-12-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% of the shares vest one year after November 27, 2017, and the balance vest in equal monthly installments thereafter over the next 36 months. Read SEC document |
| December 30, 2019 Filed Jan 2, 2020 21:39 UTC | Synthorx, Inc. THOR · Entity 152202 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 12,912 | $0.00 Strike: $0.93 | $0.00 |
DisclosureSEC source: 0001209191-20-000319 · doc4.xml · derivative · entry 8 Shawver Laura · CIK 0001551891 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,912 shares Expires 2028-05-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| December 30, 2019 Filed Jan 2, 2020 21:39 UTC | Synthorx, Inc. THOR · Entity 152202 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 98,462 | $0.00 Strike: $0.93 | $0.00 |
DisclosureSEC source: 0001209191-20-000319 · doc4.xml · derivative · entry 7 Shawver Laura · CIK 0001551891 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 293,177 Underlying: Common Stock · 98,462 shares Expires 2028-05-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 27,695 shares vest on April 12, 2019, and the remaining 363,944 shares vest in equal monthly installments thereafter over the next 36 months Read SEC document |
| December 30, 2019 Filed Jan 2, 2020 21:39 UTC | Synthorx, Inc. THOR · Entity 152202 | Tax withholdingCommon Stock | 210,010 | $70.63 | $14,833,006.30 |
DisclosureSEC source: 0001209191-20-000319 · doc4.xml · nonDerivative · entry 5 Shawver Laura · CIK 0001551891 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 296,301 Read SEC document |
| December 30, 2019 Filed Jan 2, 2020 21:39 UTC | Synthorx, Inc. THOR · Entity 152202 | Exercise / conversionCommon Stock | 120,815 | $11.00 | $1,328,965.00 |
DisclosureSEC source: 0001209191-20-000319 · doc4.xml · nonDerivative · entry 4 Shawver Laura · CIK 0001551891 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 506,311 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 30, 2019 Filed Jan 2, 2020 21:39 UTC | Synthorx, Inc. THOR · Entity 152202 | Exercise / conversionCommon Stock | 147,264 | $0.63 | $92,776.32 |
DisclosureSEC source: 0001209191-20-000319 · doc4.xml · nonDerivative · entry 3 Shawver Laura · CIK 0001551891 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 385,496 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 30, 2019 Filed Jan 2, 2020 21:39 UTC | Synthorx, Inc. THOR · Entity 152202 | Exercise / conversionCommon Stock | 12,912 | $0.93 | $12,008.16 |
DisclosureSEC source: 0001209191-20-000319 · doc4.xml · nonDerivative · entry 2 Shawver Laura · CIK 0001551891 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 238,232 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 30, 2019 Filed Jan 2, 2020 21:39 UTC | Synthorx, Inc. THOR · Entity 152202 | Exercise / conversionCommon Stock | 98,462 | $0.93 | $91,569.66 |
DisclosureSEC source: 0001209191-20-000319 · doc4.xml · nonDerivative · entry 1 Shawver Laura · CIK 0001551891 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,320 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 18, 2019 Filed Dec 19, 2019 21:41 UTC | Synthorx, Inc. THOR · Entity 152202 | GrantCommon Stock | 45,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-061311 · doc4.xml · nonDerivative · entry 1 Shawver Laura · CIK 0001551891 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,858 F1 · shares: Represents restricted stock unit award granted under the Issuer's 2018 Equity Incentive Plan. F2 · balance_after: Includes 575 shares of Common Stock that were acquired by the Reporting Person on June 14, 2019 pursuant to the Issuer's Employee Stock Purchase Plan and 577 shares of Common Stock that were acquired by the Reporting Person on December 13, 2019 pursuant to the Issuer's Employee Stock Purchase Plan. Read SEC document |
| January 24, 2019 Filed Jan 25, 2019 21:33 UTC | Synthorx, Inc. THOR · Entity 152202 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $0.63 | $0.00 |
DisclosureSEC source: 0001209191-19-005348 · doc4.xml · derivative · entry 3 Shawver Laura · CIK 0001551891 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 319,528 Underlying: Common Stock · 25,000 shares Expires 2027-12-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 25% of the shares vest one year after November 27, 2017, and the balance vest in equal monthly installments thereafter over the next 36 months. Read SEC document |
| January 24, 2019 Filed Jan 25, 2019 21:33 UTC | Synthorx, Inc. THOR · Entity 152202 | Exercise / conversionCommon Stock | 25,000 | $0.63 | $15,750.00 |
DisclosureSEC source: 0001209191-19-005348 · doc4.xml · nonDerivative · entry 1 Shawver Laura · CIK 0001551891 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Laura K. Shawver Trust DTD 3/20/2000 Disclosed balance after: 25,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · ownership.direct: The shares acquired upon the exercise of the employee stock option were issued in the name of the Reporting Person's trust and are held indirectly. Read SEC document |
| December 06, 2018 Filed Dec 7, 2018 22:30 UTC | Synthorx, Inc. THOR · Entity 152202 | GrantEmployee Stock Option (right to buy) · Derivative | 506,000 | $0.00 Strike: $11.00 | $0.00 |
DisclosureSEC source: 0001209191-18-061557 · doc4.xml · derivative · entry 1 Shawver Laura · CIK 0001551891 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 506,000 Underlying: Common Stock · 506,000 shares Expires 2028-12-05 F1 · derivative.exercise_date: 100% of the shares subject to the option vest upon certification by the Compensation Committee of the Board of Directors of the Issuer that the Issuer has received the first approval for commercial sale by a regulatory authority of any product candidate of the Issuer in any territory in the world. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.